Connect Biopharma Regains Nasdaq Compliance with Minimum Bid Price Requirement
Reuters
Jul 17
Connect Biopharma Regains Nasdaq Compliance with Minimum Bid Price Requirement
Connect Biopharma Holdings Ltd. announced on July 17, 2025, that it has regained compliance with the Nasdaq minimum bid price requirement. The biopharmaceutical company, focused on treatments for inflammatory diseases, confirmed that its American Depositary Shares maintained a minimum closing bid price of at least $1.00 for 10 consecutive business days, as of July 15, 2025. This compliance allows the company's shares to continue being listed and traded on Nasdaq, resolving the regulatory issue.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9496024-en) on July 17, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.